We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
-7.97%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$252M
AUM Growth
-$77.3M
Cap. Flow
+$26.1M
Cap. Flow %
10.33%
Top 10 Hldgs %
81.34%
Holding
31
New
5
Increased
9
Reduced
8
Closed
3

Top Buys

1
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$62.6M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$7.41M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$5.15M
4
BPMC
Blueprint Medicines
BPMC
+$4.96M
5
SGMT icon
Sagimet Biosciences
SGMT
+$4.64M

Top Sells

1
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$46.9M
2
SLRN
ACELYRIN
SLRN
+$8.51M
3
IRON icon
Disc Medicine
IRON
+$5.01M
4
PLRX icon
Pliant Therapeutics
PLRX
+$1.78M
5
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$1.62M

Sector Composition

1 Healthcare 98.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLRX icon
1
Pliant Therapeutics
PLRX
$71.2M
$52.3M 20.72%
3,014,199
-102,818
-3% -$1.78M
RPTX
2
DELISTED
Repare Therapeutics
RPTX
$35.8M 14.2%
2,966,674
-32,060
-1% -$331K
CGEM icon
3
Cullinan Oncology
CGEM
$1.09B
$30.9M 12.25%
3,414,189
– –
SLRN
4
DELISTED
ACELYRIN
SLRN
$23M 9.12%
2,262,990
-400,816
-15% -$8.51M
ORTX
5
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$14M 5.56%
12,315,654
+11,559,916
+1,530% +$62.6M
LRMR icon
6
Larimar Therapeutics
LRMR
$384M
$13.5M 5.35%
3,414,468
– –
KROS icon
7
Keros Therapeutics
KROS
$211M
$13M 5.15%
407,633
+5,515
+1% +$206K
IMA
8
ImageneBio Inc
IMA
$60.7M
$9.44M 3.74%
181,745
+4,908
+3% +$296K
RARE icon
9
Ultragenyx Pharmaceutical
RARE
$2.88B
$7.66M 3.04%
215,000
+130,000
+153% +$5.15M
CMPX icon
10
Compass Therapeutics
CMPX
$369M
$5.57M 2.21%
2,829,712
– –
MLYS icon
11
Mineralys Therapeutics
MLYS
$2.39B
$5.41M 2.14%
+568,379
New +$7.41M
INZY
12
DELISTED
Inozyme Pharma
INZY
$5.33M 2.11%
1,270,027
+75,000
+6% +$382K
SYRS
13
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.12M 2.03%
1,299,359
+531,914
+69% +$1.99M
BPMC
14
DELISTED
Blueprint Medicines
BPMC
$4.66M 1.85%
+92,888
New +$4.96M
LABD icon
15
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$75.8M
$4.63M 1.84%
22,500
-10,000
-31% -$1.62M
TSVT
16
DELISTED
2seventy bio
TSVT
$3.93M 1.56%
1,002,007
+150,000
+18% +$984K
MLTX icon
17
MoonLake Immunotherapeutics
MLTX
$1.64B
$3.42M 1.36%
+60,000
New +$3.31M
OVID icon
18
Ovid Therapeutics
OVID
$455M
$3.32M 1.32%
864,822
– –
SGMT icon
19
Sagimet Biosciences
SGMT
$483M
$3.07M 1.22%
+348,842
New +$4.64M
OMGA
20
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$2.27M 0.9%
1,055,882
– –
BDTX icon
21
Black Diamond Therapeutics
BDTX
$103M
$2.07M 0.82%
720,000
-30,000
-4% -$111K
RLYB icon
22
Rallybio
RLYB
$87.1M
$1.32M 0.52%
48,842
-19,005
-28% -$823K
IRON icon
23
Disc Medicine
IRON
$2.91B
$1.17M 0.47%
25,000
-100,139
-80% -$5.01M
LENZ
24
LENZ Therapeutics
LENZ
$162M
$573K 0.23%
32,991
– –
FRLN
25
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$373K 0.15%
86,654
+64,988
+300% +$257K
1
2

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, CHI Advisors held 31 positions worth $252M, down 23% from $330M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

CHI Advisors deployed $26.1M of net new capital in Q3 2023, opening 5 new positions and adding to 9 existing holdings. Its largest new stake was Mineralys Therapeutics: 568,379 shares worth $5.41M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was ACELYRIN, an estimated $8.51M trimmed.

  • CHI Advisors's largest Q3 2023 buy was Mineralys Therapeutics: 568,379 shares worth $5.41M.
  • CHI Advisors added most to Orchard Therapeutics plc American Depositary Shares in Q3 2023, an estimated $62.6M increase.
  • CHI Advisors's biggest Q3 2023 reduction was ACELYRIN, cutting an estimated $8.51M.
  • CHI Advisors fully exited VectivBio Holding AG Ordinary Shares in Q3 2023, selling an estimated $46.9M.
  • CHI Advisors's ten largest holdings make up 81% of its $252M portfolio in Q3 2023.
  • CHI Advisors opened 5 new positions and closed 3 in Q3 2023.
  • CHI Advisors's portfolio value fell 23% quarter-over-quarter to $252M.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.